4 results on '"Robles, Alejandro Pallares"'
Search Results
2. Clinical profile and outcome of isolated pulmonary embolism: a systematic review and meta-analysis
- Author
-
ten Cate, Vincent, Prochaska, Jürgen H., Schulz, Andreas, Nagler, Markus, Robles, Alejandro Pallares, Jurk, Kerstin, Koeck, Thomas, Rapp, Steffen, Düber, Christoph, Münzel, Thomas, Konstantinides, Stavros V., and Wild, Philipp S.
- Published
- 2023
- Full Text
- View/download PDF
3. Autoantibodies against the chemokine receptor 3 predict cardiovascular risk.
- Author
-
Müller, Felix S, Aherrahrou, Zouhair, Grasshoff, Hanna, Heidorn, Marc W, Humrich, Jens Y, Johanson, Laurence, Aherrahrou, Redouane, Reinberger, Tobias, Schulz, Andreas, Cate, Vincent ten, Robles, Alejandro Pallares, Koeck, Thomas, Rapp, Steffen, Lange, Tanja, Brachaczek, Lukas, Luebber, Finn, Erdmann, Jeanette, Heidecke, Harald, Schulze-Forster, Kai, and Dechend, Ralf
- Subjects
CHEMOKINE receptors ,HEART failure ,BRAIN natriuretic factor ,G protein coupled receptors ,AUTOANTIBODIES ,CAROTID intima-media thickness - Abstract
Background and Aims Chronic inflammation and autoimmunity contribute to cardiovascular (CV) disease. Recently, autoantibodies (aAbs) against the CXC-motif-chemokine receptor 3 (CXCR3), a G protein-coupled receptor with a key role in atherosclerosis, have been identified. The role of anti-CXCR3 aAbs for CV risk and disease is unclear. Methods Anti-CXCR3 aAbs were quantified by a commercially available enzyme-linked immunosorbent assay in 5000 participants (availability: 97.1%) of the population-based Gutenberg Health Study with extensive clinical phenotyping. Regression analyses were carried out to identify determinants of anti-CXCR3 aAbs and relevance for clinical outcome (i.e. all-cause mortality, cardiac death, heart failure, and major adverse cardiac events comprising incident coronary artery disease, myocardial infarction, and cardiac death). Last, immunization with CXCR3 and passive transfer of aAbs were performed in ApoE
(−/−) mice for preclinical validation. Results The analysis sample included 4195 individuals (48% female, mean age 55.5 ± 11 years) after exclusion of individuals with autoimmune disease, immunomodulatory medication, acute infection, and history of cancer. Independent of age, sex, renal function, and traditional CV risk factors, increasing concentrations of anti-CXCR3 aAbs translated into higher intima–media thickness, left ventricular mass, and N-terminal pro-B-type natriuretic peptide. Adjusted for age and sex, anti-CXCR3 aAbs above the 75th percentile predicted all-cause death [hazard ratio (HR) (95% confidence interval) 1.25 (1.02, 1.52), P =.029], driven by excess cardiac mortality [HR 2.51 (1.21, 5.22), P =.014]. A trend towards a higher risk for major adverse cardiac events [HR 1.42 (1.0, 2.0), P =.05] along with increased risk of incident heart failure [HR per standard deviation increase of anti-CXCR3 aAbs: 1.26 (1.02, 1.56), P =.03] may contribute to this observation. Targeted proteomics revealed a molecular signature of anti-CXCR3 aAbs reflecting immune cell activation and cytokine–cytokine receptor interactions associated with an ongoing T helper cell 1 response. Finally, ApoE(−/−) mice immunized against CXCR3 displayed increased anti-CXCR3 aAbs and exhibited a higher burden of atherosclerosis compared to non-immunized controls, correlating with concentrations of anti-CXCR3 aAbs in the passive transfer model. Conclusions In individuals free of autoimmune disease, anti-CXCR3 aAbs were abundant, related to CV end-organ damage, and predicted all-cause death as well as cardiac morbidity and mortality in conjunction with the acceleration of experimental atherosclerosis. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
4. Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thrombosis.
- Author
-
Akbulut AC, Arisz RA, Baaten CCFMJ, Baidildinova G, Barakzie A, Bauersachs R, Ten Berg J, van den Broek WWA, de Boer HC, Bonifay A, Bröker V, Buka RJ, Ten Cate H, Ten Cate-Hoek AJ, Cointe S, De Luca C, De Simone I, Diaz RV, Dignat-George F, Freson K, Gazzaniga G, van Gorp ECM, Habibi A, Henskens YMC, Iding AFJ, Khan A, Koenderink GH, Konkoth A, Lacroix R, Lahiri T, Lam W, Lamerton RE, Lorusso R, Luo Q, Maas C, McCarty OJT, van der Meijden PEJ, Meijers JCM, Mohapatra AK, Nevo N, Robles AP, Poncelet P, Reinhardt C, Ruf W, Saraswat R, Schönichen C, Schutgens R, Simioni P, Spada S, Spronk HMH, Tazhibayeva K, Thachil J, Diaz RV, Vallier L, Veninga A, Verhamme P, Visser C, Watson SP, Wenzel P, Willems RAL, Willers A, Zhang P, Zifkos K, and van Zonneveld AJ
- Subjects
- Humans, Anticoagulants therapeutic use, Blood Coagulation, Hemostasis, Hemorrhage drug therapy, COVID-19, Thrombosis, Blood Coagulation Disorders drug therapy
- Abstract
The Fourth Maastricht Consensus Conference on Thrombosis included the following themes. Theme 1: The "coagulome" as a critical driver of cardiovascular disease. Blood coagulation proteins also play divergent roles in biology and pathophysiology, related to specific organs, including brain, heart, bone marrow, and kidney. Four investigators shared their views on these organ-specific topics. Theme 2: Novel mechanisms of thrombosis. Mechanisms linking factor XII to fibrin, including their structural and physical properties, contribute to thrombosis, which is also affected by variation in microbiome status. Virus infection-associated coagulopathies perturb the hemostatic balance resulting in thrombosis and/or bleeding. Theme 3: How to limit bleeding risks: insights from translational studies. This theme included state-of-the-art methodology for exploring the contribution of genetic determinants of a bleeding diathesis; determination of polymorphisms in genes that control the rate of metabolism by the liver of P2Y12 inhibitors, to improve safety of antithrombotic therapy. Novel reversal agents for direct oral anticoagulants are discussed. Theme 4: Hemostasis in extracorporeal systems: the value and limitations of ex vivo models. Perfusion flow chamber and nanotechnology developments are developed for studying bleeding and thrombosis tendencies. Vascularized organoids are utilized for disease modeling and drug development studies. Strategies for tackling extracorporeal membrane oxygenation-associated coagulopathy are discussed. Theme 5: Clinical dilemmas in thrombosis and antithrombotic management. Plenary presentations addressed controversial areas, i.e., thrombophilia testing, thrombosis risk assessment in hemophilia, novel antiplatelet strategies, and clinically tested factor XI(a) inhibitors, both possibly with reduced bleeding risk. Finally, COVID-19-associated coagulopathy is revisited., Competing Interests: None declared., (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.